Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Statin-associated weakness in myasthenia gravis: a case report

  • Michael J Keogh1Email author,
  • John M Findlay1,
  • Simon Leach1 and
  • John Bowen1
Journal of Medical Case Reports20104:61

DOI: 10.1186/1752-1947-4-61

Received: 29 January 2008

Accepted: 20 February 2010

Published: 20 February 2010

Abstract

Introduction

Myasthenia gravis is a commonly undiagnosed condition in the elderly. Statin medications can cause weakness and are linked to the development and deterioration of several autoimmune conditions, including myasthenia gravis.

Case presentation

We report the case of a 60-year-old Caucasian man who presented with acute onset of dysarthria and dysphagia initially attributed to a brain stem stroke. Oculobulbar and limb weakness progressed until myasthenia gravis was diagnosed and treated, and until statin therapy was finally withdrawn.

Conclusion

Myasthenia gravis may be underappreciated as a cause of acute bulbar weakness among the elderly. Statin therapy appeared to have contributed to the weakness in our patient who was diagnosed with myasthenia gravis.

Introduction

Myasthenia gravis (MG) is characterised by fatigable muscle weakness and has an incidence of only 1 in 5 to 10,000 people [1]. Autoimmune myasthenia gravis, often in association with thymus hyperplasia or thymoma, can affect young adults. However, it is now recognized that myasthenia gravis is actually more prevalent in middle-aged and older groups than younger age groups [2]. In elderly patients, bulbar presentation is common [3] and often mislabeled as a stroke [4] leading to poorer rates of survival [5].

Statins (inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase) lower the incidence of cerebrovascular disease and coronary heart disease. Statin use has increased dramatically over the last decade, with a four-fold increase from 1996 to 1998 [6].

Although generally well-tolerated, statins may have primary care discontinuation rates of up to 30% [7] due to their side effects such as headache, myalgia, paraesthesia, and abdominal discomfort.

Here, we report a case of acute myasthenia gravis presenting in a 60-year-old Caucasian man whose condition deteriorated until immunosuppressive therapy was commenced and statin therapy was withdrawn.

Case presentation

A 60-year-old Caucasian man of British origin was admitted to our hospital in September 2007 following acute onset of dysarthria and dysphagia. He was diagnosed with diabetes mellitus and hyperlipidaemia three months prior to presentation.

He had no visual disturbance or sensorimotor symptoms in his limbs or torso on presentation. He was commenced on gliclazide, ramipril and aspirin when he was diagnosed with diabetes and hyperlipidemia 3 months earlier. He was also started on simvastatin at that time, but this was stopped following the development of proximal muscle weakness, myalgia, and an elevated creatine kinase (CK) of 2599 (normal: <200), which all resolved upon the termination of this medication. Gliclazide, ramipril and aspirin, however, were continued.

Aside from the finding of mild dysarthria, examination revealed that our patient had no remarkable conditions. Results of routine haematology, biochemistry, thyroid function tests, and creatine kinase were also unremarkable. His serum cholesterol was 6.1 mmol/L and his random blood glucose was 11.2 mmol/L.

An initial diagnosis of a brain stem stroke was considered, so dipyridamole and atorvastatin were added to his medication four days after his admission to our hospital. Meanwhile, a computed tomography (CT) brain scan showed that he had no obvious infarct.

Our patient remained stable over the next few days with a mild dysarthria and dysphagia (tolerating soft food), but no other symptoms or signs were noted.

One week after his admission to our hospital, his dysarthria and dysphagia worsened. Bilateral fatigable ptosis, diplopia, fatigable weakness of his neck flexion, and shoulder abduction were noted for the first time. A previously planned cranial magnetic resonance brain scan was thus cancelled.

Edrophonium testing demonstrated a dramatic transient improvement in his dysarthria, and a diagnosis of myasthenia gravis with high titre anti-acetylcholine receptor antibodies was confirmed. A serum immunoglobulin assay revealed an IgA level of <0.05 g/L. He was noted to have normal IgG and IgM, and no paraprotein band.

Our patient was then commenced on treatment with pyridostigmine. He was also started on incrementally increasing prednisolone every other day. Regular monitoring of his respiratory function was also initiated.

His respiratory function worsened over the next 3 days. His spirometry also deteriorated. He developed a new fatigable diplopia and an inability to stand from a low squat position, together with increasing neck and proximal limb weakness.

In view of his deteriorating state, intravenous immunoglobulin therapy (IVIg) was commenced. Following immunological advice regarding his low IgA titre, it was decided to use Vigam Immunoglobulin (2 g/kg over the next 4 days), which did not result in any adverse effect.

No objective gains were noted over the subsequent week, and a repeat CK yielded a result of 842 mmol/L. His atorvastatin medication was then stopped two weeks after it had been introduced. Following this, our patient showed significant improvement in ptosis, a resolution of diplopia, and improved neck, shoulder, and elbow power. His ability to stand from a low squat position returned, and significant spirometric improvements were also seen.

His CK readings fell over this period and returned to normal levels one week after the cessation of his statin medication (Figure 1).
https://static-content.springer.com/image/art%3A10.1186%2F1752-1947-4-61/MediaObjects/13256_2008_Article_1023_Fig1_HTML.jpg
Figure 1

This image of a graph shows creatinine kinase readings during admission, and a correlation to clinical progress.

Our patient remained stable until two weeks later when, just prior to a planned discharge, a further deterioration and unresponsiveness to a second course of IVIg necessitated respiratory and nutritional support, intensive care, and plasma exchange.

Following prolonged treatment, his muscle strength improved and he returned to independent living at home four months after his admission to our hospital. His gastrostomy feeding tube and tracheostomy were removed 10 months after he was discharged from our hospital.

Discussion

Myasthenia gravis has an incidence of only 1 in every 5 to 10,000 people and is potentially fatal. A recent study suggests that 2.2% of patients admitted with myasthenia gravis overall died during admission [8], and that the risk could be reduced by 69% if the patient is under the care of a neurologist. It is thus important not to readily dismiss the condition and that appropriate referrals are made.

The actual incidence of statin-exacerbated myasthenia is unknown, and only a handful of reports of statin-associated myasthenia gravis have ever been described [911].

Out of 6 published case reports, only 5 patients were noted to have some degree of recovery and only one patient had a complete recovery upon termination of statin therapy [11].

How statins could appear to exacerbate MG is unclear. It is possible that the mechanism actually reflects a "double hit" phenomenon of defective neuromuscular transmission secondary to antibody-mediated post-synaptic acetylcholine receptor dysfunction in combination with a statin-induced myopathy.

The clear development of a statin myopathy with simvastatin treatment prior to the onset of myasthenia in our patient is consistent with the possibility of a second (atorvastatin- induced) myopathy coalescing with the onset of myasthenia gravis. The symptomatic improvement that followed his withdrawal from atorvastatin treatment resulted from the resolution of this statin myopathy.

We also considered other potential causes of deterioration such as sepsis, steroid-induced worsening of MG, steroid myopathy, and cholinergic crisis, but we considered their development less likely based on clinical grounds.

We cannot rule out completely the possibility that the worsening of our patient's MG simply reflected a progression of his MG. However, the clinical course of his condition, as well as the statin-induced proximal limb pain and weakness (without bulbar features) he experienced prior to his presentation, raises at the very least the possibility that a component of his initial deterioration was statin-related.

Similarly, we note that his improvement could have reflected the immunosuppressive effects of therapy for his MG rather than the withdrawal of his atorvastatin treatment. It seems probable, however, that both factors played a significant role in the improvement of his clinical state.

The development of other autoimmune disorders such as dermatomyositis [12], polymyalgia rheumatica, vasculitis [13], and Lupus-like syndrome [14] upon initiation of statin therapy [13] raises the possibility that in predisposed individuals, statins may precipitate an immunological trigger that is analogous to penicillamine-induced MG [15] although clearly different in temporal respect. However, given the paucity of reports and the widespread use of statins, the possibility of chance association cannot be excluded still.

Conclusion

Myasthenia gravis is a potentially fatal condition that should be considered in elderly patients with bulbar symptoms. Statin medication should be introduced cautiously and considered as a potential cause or precipitant of worsening muscle strength in patients with myasthenia gravis.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CK: 

creatinine kinase

CT: 

computed tomography

IVIg: 

intravenous immunoglobulins

MG: 

myasthenia gravis.

Declarations

Acknowledgements

None

Authors’ Affiliations

(1)
Department of Stroke Medicine, United Lincolnshire Hospitals Trust, Lincoln County Hospital

References

  1. Vincent A, Palace J, Hilton-Jones D: Myasthenia gravis. Lancet. 2001, 357: 2122-2128. 10.1016/S0140-6736(00)05186-2.View ArticlePubMedGoogle Scholar
  2. Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J: Late-onset myasthenia gravis: follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci. 1998, 841: 777-780. 10.1111/j.1749-6632.1998.tb11017.x.View ArticlePubMedGoogle Scholar
  3. Vincent A, Clover L, Buckley V, Evans JG, Rothwell PM: Evidence of underdiagnosis of myasthenia gravis in older People. J Neurol Neurosurg Psychiatry. 2003, 74: 1105-1108. 10.1136/jnnp.74.8.1105.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Kleiner-Fisman G, Kott HS: Myasthenia gravis mimicking stroke in elderly patients. Mayo Clin Proc. 1998, 73: 1077-1078. 10.4065/73.11.1077.View ArticlePubMedGoogle Scholar
  5. Christensen PB, Jensen TS, Tsiropoulos I, Sorensen T, Kjaer M, Hojer-Pedersen E, Rasmussen M, Lehfeldt E: Mortality and survival in myasthenia gravis: a Danish population-based study. J Neurol Neurosurg Psychiatry. 1998, 64: 78-83. 10.1136/jnnp.64.1.78.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Packham C, Pearson J, Robinson J, Gray D: Use of statins in general practices, 1996-1998: a cross sectional study. BMJ. 2000, 320: 1583-1584. 10.1136/bmj.320.7249.1583.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Simons LA, Simons J: Discontinuation rates of statins are high. BMJ. 2000, 321: 1084-10.1136/bmj.321.7268.1084.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Hill M, Ben-Shlomo Y: Neurological care and risk of hospital mortality for patients with myasthenia gravis in England. J Neurol Neurosurg Psychiatry. 2008, 79 (4): 421-425. 10.1136/jnnp.2007.118950.View ArticlePubMedGoogle Scholar
  9. Prvin A, Kawasaki A, Smith K, Kestler A: Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore). 2006, 85: 82-85. 10.1097/01.md.0000209337.59874.aa.View ArticleGoogle Scholar
  10. Cartwright M, Jeffery D, Nuss G, Donofrio P: Statin-associated exacerbation of myasthenia gravis. Neurology. 2004, 63: 2188-View ArticlePubMedGoogle Scholar
  11. Parmar B, Francis P, Ragge N: Statins, fibrates and ocular myasthenia. Lancet. 2002, 360: 717-10.1016/S0140-6736(02)09846-X.View ArticlePubMedGoogle Scholar
  12. Khattak FH, Morris IM, Branford WA: Simvastatin-associated dermatomyositis. Br J Rheumatology. 1994, 33: 199-10.1093/rheumatology/33.2.199.View ArticleGoogle Scholar
  13. Rudski L, Rabinovitch M, Danoff D: Systemic immune reactions to HMG-CoA reductase inhibitors: a report of 4 cases and review of the literature. Medicine. 1998, 77: 378-383. 10.1097/00005792-199811000-00002.View ArticlePubMedGoogle Scholar
  14. Ahmad S: Lovastatin-induced lupus erthymatosus. Arch Int Med. 1991, 151: 1667-1668. 10.1001/archinte.151.8.1667.View ArticleGoogle Scholar
  15. Wittbrodt E: Drugs and myasthenia gravis: an update. Arch Int Med. 1997, 157: 399-408. 10.1001/archinte.157.4.399.View ArticleGoogle Scholar

Copyright

© Keogh et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.